About this trial

Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms

Eligibility criteria

Qualifiers

Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis)

Patient who has not received treatment specific to hemopathy at the time of sampling

Obtaining the signature of consent to participate in the study

Patient having consented to be included in the "Malignant Hemopathy" collection of Angers University Hospital and in FIMBANK database

Disqualifiers

Person not affiliated to a social security scheme or beneficiary of such a scheme

Patient with another hemopathy or another active cancer at the time of diagnosis

Minor patient at diagnosis (< 18 years old)

Patient not capable or without agreement from the guardian or legal representative

Trial design

Treatments tested in this trial

  • Monocytes signatures in myeloproliferative neoplasms at diagnosis

Treatment groups

70 Participants
are divided into 1 treatment group

Locations

3
GOUBAND Agathe49933, AngersMaine et Loire, France
BESCOND Charles49325, CholetMaine et Loire, France
TRUCHAN-GRACZYK Malgorzata49400, SaumurMaine et Loire, France

Sponsors and collaborators

University Hospital, Angers

Lead sponsor